Up­dat­ed: No­var­tis close to ac­quir­ing Cy­to­ki­net­ics af­ter biotech's PhI­II heart dis­ease win — WSJ

No­var­tis is in dis­cus­sions to buy Cy­to­ki­net­ics, the Wall Street Jour­nal re­port­ed Mon­day, send­ing the biotech’s stock $CYTK soar­ing near­ly 15%.

The deal could be sealed be­fore the end of the week, per WSJ. No­var­tis de­clined to com­ment.

Mon­day’s re­port comes af­ter Cy­to­ki­net­ics re­leased pos­i­tive Phase III da­ta for a heart dis­ease pro­gram, known as afi­camten, set­ting up a po­ten­tial show­down with Bris­tol My­ers Squibb’s Camzyos and spark­ing M&A spec­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER